AIPLA Biotechnology Committee Webinar: Mayo v. Prometheus: Did the Bell Toll for Personalized Medicine Patents? Prof. Joshua D. Sarnoff DePaul U. College.

Slides:



Advertisements
Similar presentations
In re Bilski Federal Circuit (2008) (en banc) Decided: October 30, 2008 A very SMALL decision on a very BIG issue!
Advertisements

Navigating the Post- Prometheus World Technology Transfer Tactics Webinar May 3, 2012 Kevin E. Noonan, Ph.D.
Technology Center 1600 Training on Writing Rejections Under 35 U.S.C. § 103.
1 1 1 AIPLA Firm Logo American Intellectual Property Law Association CLS BANK: PATENT ELIGIBILITY UNDER SECTION 101 JIPA/AIPLA Meeting By Joseph A. Calvaruso.
Second level — Third level Fourth level »Fifth level CLS Bank And Its Aftermath Presented By: Joseph A. Calvaruso Orrick, Herrington & Sutcliffe LLP ©
CAMBRIDGE UNIVERSITY UK Robinson College – Faculty of Law 23rd Annual Fordham Conference Intellectual Property Law and Policy 8 – 9 April 2015 Patent Session.
Orlando, Florida | Mayo v. Prometheus by:Jon M. Gibbs Lowndes, Drosdick, Doster, Kantor and Reed PA.
Diagnostics: Patent Eligibility and the Industry Perspective
Mayo – The Bell Tolled or, It’s the End of the World as We Know It (And I Feel Fine) May 3, 2012 AIPLA Biotechnology Committee Webinar James J. Kelley.
What is Happening to Patent Eligibility and What Can We Do About It? June 24, 2014 Bruce D. Sunstein Denise M. Kettelberger, Ph.D. Sunstein Kann Murphy.
1 1 AIPLA 1 1 American Intellectual Property Law Association Patentable Subject Matter in the US AIPPI-Symposium Zeist 13 March 2013 Raymond E. Farrell.
PATENTABLE SUBJECTS IN THE INTERNET OF THINGS ALICIA SHAH.
Mayo v. Prometheus Decided March 20, 2012 Roberte Makowski, Ph.D., J.D. Hans Sauer, Ph.D., J.D.
More on Section 101 Patent Law Prof. Merges
Wolf, Greenfield & Sacks, P.C. | 600 Atlantic Avenue | Boston, Massachusetts | | fax | wolfgreenfield.com Recent Developments.
Intellectual Property March 4, 2015 Don Keach Director, Intellectual Property Development and Technology Transfer Office Copyright University of Kentucky.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
* Statements of fact and opinions expressed are those of the speaker individually and are not the opinion or position of Research In Motion Limited or.
In re Bilski (Fed Cir. 2008) Patentable subject matter In re Bilski (Fed Cir. 2008) Patentable subject matter December 2, 2008 John King Ron Schoenbaum.
ISMT 520 Lecture #6: Protecting Technical and Business Process Innovations Dr. Theodore H. K. Clark Associate Professor and Academic Director of MSc Programs.
Intellectual Property Boston College Law School March 3, 2008 Patent - Nonobviousness.
Patents 101 April 1, 2002 And now, for something new, useful and not obvious.
1 1 AIPLA Firm Logo American Intellectual Property Law Association Myriad Guidance for Biotechnology and Chemical Practice Joerg-Uwe Szipl Griffin and.
Medical Device Partnership: USPTO Interim Eligibility Guidance Michael Cygan, USPTO June 2, 2015.
Examiner Guidelines After Alice Corp. August 21, 2014 How Much “More” is “Significantly More”?
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
LOGIC AND CRITICAL THINKING Jonathan Dolhenty, Ph.D. Logic and Critical Thinking. Available at
35 USC 101 Update Business Methods Partnership Meeting, Spring 2008 by Robert Weinhardt Business Practice Specialist, Technology Center 3600
Biotechnology/Chemical/Pharmaceutical Customer Partnership: Recent Examiner Training and Developments Under 35 USC § 101 Drew Hirshfeld Deputy Commissioner.
McGraw-Hill © 2006 The McGraw-Hill Companies, Inc. All rights reserved. The Nature of Research Chapter One.
Patent Prosecution Luncheon March White House Patent Reform: Executive Actions Draft rule to ensure patent owners accurately record and regularly.
Judicially Created Diversity in Patent Law Norman Siebrasse Professor of Law University of New Brunswick, Canada.
INVENTION DISCLOSURE WRITING WORKSHOP May 6, 2004 Presented by: Hunter Auyang Bella Fishman.
California :: Delaware :: Florida :: New Jersey :: New York :: Pennsylvania :: Virginia :: Washington, DC :: Advice for Drafting.
Post-Prometheus Interim Examination Guidelines Daphne Lainson Smart & Biggar AIPLA 1.
Post-Bilski Patent Prosecution IP Osgoode March 13, 2009 Bob Nakano McCarthy Tétrault LLP.
Josiah Hernandez Patentability Requirements. Useful Having utilitarian or commercial value Novel No one else has done it before If someone has done it.
Intellectual Property Law © 2007 IBM Corporation EUPACO 2 – The European Patent Conference 16 May 2007 Patent Quality Roger Burt IBM Europe.
Patentability Considerations in the 3-D Structure Arts Patentability Considerations in the 3-D Structure Arts Michael P. Woodward Supervisory Patent Examiner.
Overview Validity of patent hinges on novelty, utility, and non-obviousness Utility generally not an issue Pre-suit investigation focuses on infringement,
Trilateral Project WM4 Report on comparative study on Examination Practice Relating to Single Nucleotide Polymorphisms (SNPs) and Haplotypes. Linda S.
AMP v. US PTO: Section 101 and DNA Sequence Patents Joshua D. Sarnoff DePaul U. College of Law 25 E. Jackson Blvd. Chicago, IL,
Patents IV Nonobviousness
1 1 AIPLA Firm Logo American Intellectual Property Law Association More Fun with A Prosecution Perspective on the Protection of Computer Implemented.
Mayo v. Prometheus Labs – The Backdrop June 12, 2012 © 2012, all rights reserved.
Patentable Subject Matter Donald M. Cameron. 2 Patents: The Bargain Public: gets use of invention after patent expires Inventor/Owner: gets limited monopoly.
Nonobviousness II: More on Nonobviousness The Scope & Content of the Prior Art Law 677 | Patent Law | Spring 2002 Administrative: (1)reminder: Federal.
What is Patentable Subject Matter? Dan L. Burk Chancellor’s Professor of Law University of California, Irvine.
Patents and the Patenting Process Patents and the Inventor’s role in the Patenting Process.
Interim Guidance on Patent Subject Matter Eligibility Raul Tamayo, USPTO July 13, 2015.
Writing a Classical Argument
Assistant Instructor Nian K. Ghafoor Feb Definition of Proposal Proposal is a plan for master’s thesis or doctoral dissertation which provides the.
Class 24: Finish Remedies, then Subject Matter Patent Law Spring 2007 Professor Petherbridge.
Interim Eligibility Guidance: Life Sciences Example Workshop I.
Patents 101 March 28, 2006 And now, for something new, useful and not obvious.
Jody Blanke, Professor Computer Information Systems and Law 1.
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP AIPLA BIOTECHNOLOGY COMMITTEE WEBINAR Leslie McDonell The contents of.
Patents 101 March 28, 2006 And now, for something new, useful and not obvious.
The Challenge of Biotech Patent Eligibility in the United States:
Alexandria, Virginia July 21, 2014
PATENTS IT.CAN Annual Meeting
Patents IV Nonobviousness
The Mayo-Alice Dogma and Paths to Eligibility for BioPharma
Global Innovation Management Workout on Writing a Patent
MOPOP chapter 17- Kits Training
Recent USPTO Developments on Subject Matter Eligibility
Patentable Subject Matter
Virtual Instructor Led Training (vILT) February 26, 27 and 28, 2019
Subject Matter Eligibility
A tutorial and update on patentable subject matter
Presentation transcript:

AIPLA Biotechnology Committee Webinar: Mayo v. Prometheus: Did the Bell Toll for Personalized Medicine Patents? Prof. Joshua D. Sarnoff DePaul U. College of Law Chicago, IL, USA May 3, 2012

Question the Court Answered “The question before us is whether the claims do significantly more than simply describe these natural relations. To put the matter more precisely, do the patent claims add enough to their statements of the correlations to allow the processes they describe to qualify as patent-eligible processes that apply natural laws? We believe that the answer to this question is no.”

Implications of the Court’s Q&A 1.Natural medical correlations, even if produced synthetically, are “laws of nature” excluded from patent eligibility “While it takes a human action (the administration of a thiopurine drug) to trigger a manifestation of this relation in a particular person, the relation itself exists in principle apart from any human action. The relation is a consequence of the ways in which thiopurine compounds are metabolized by the body—entirely natural processes. And so a patent that simply describes that relation sets forth a natural law.”

Implications of the Court’s Q&A 2. Merely making practical application of such newly discovered correlations (information) is not by itself enough to impart eligibility “The process that each claim recites tells doctors interested in the subject about the correlations that the researchers discovered. In doing so, it recites an “administering” step, a “determining” step, and a “wherein” step. These additional steps are not themselves natural laws but neither are they sufficient to transform the nature of the claim.”

Implications of the Court’s Q&A 3. More is needed than adding newly discovered information to conventional or obvious activity (in light of the information) “To put the matter more succinctly, the claims inform a relevant audience about certain laws of nature; any additional steps consist of well-understood, routine, conventional activity already engaged in by the scientific community; and those steps, when viewed as a whole, add nothing significant beyond the sum of their parts taken separately. For these reasons we believe that the steps are not sufficient to transform unpatentable natural correlations into patentable applications of those regularities.”

Implications of the Court’s Q&A 4. What appears needed is a non-obvious “inventive concept” – as newly discovered information must be considered prior art “Those [precedential] cases warn us against interpreting patent statutes in ways that make patent eligibility “depend simply on the draftsman's art” without reference to the “principles underlying the prohibition against patents for [natural laws].”… [T]hey insist that a process that focuses upon the use of a natural law also contain other elements or a combination of elements, sometimes referred to as an “inventive concept,” sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the natural law itself.” “Intuitively, one would suppose that a newly discovered law of nature is novel. The Government, however, suggests in effect that the novelty of a component law of nature may be disregarded when evaluating the novelty of the whole. … But §§ 102 and 103 say nothing about treating laws of nature as if they were part of the prior art when applying those sections….. These considerations lead us to decline the Government's invitation to substitute §§ 102, 103, and 112 inquiries for the better established inquiry under § 101.”§§ §§ § 101

Confusion over the Court’s Approach– preemption v. creativity 5. Court’s concern for preemption/breadth of the application only, or also for conventional but more limited applications? “They warn us against upholding patents that claim processes that too broadly preempt the use of a natural law…. In particular, the steps in the claimed processes (apart from the natural laws themselves) involve well-understood, routine, conventional activity previously engaged in by researchers in the field. At the same time, upholding the patents would risk disproportionately tying up the use of the underlying natural laws, inhibiting their use in the making of further discoveries.” “If a law of nature is not patentable, then neither is a process reciting a law of nature, unless that process has additional features that provide practical assurance that the process is more than a drafting effort designed to monopolize the law of nature itself.”

What limited applications are “inventive concepts” and not mere “drafting exercises” 6. More than mere specificity or application limits, but how much creativity (i.e., non-obvious addition to the discovered information)? “Other cases offer further support for the view that simply appending conventional steps, specified at a high level of generality, to laws of nature, natural phenomena, and abstract ideas cannot make those laws, phenomena, and ideas patentable.” Morse describing Neilson: “Thus, the claimed process included not only a law of nature but also several unconventional steps (such as inserting the receptacle, applying heat to the receptacle externally, and blowing the air into the furnace) that confined the claims to a particular, useful application of the principle.”